Intelligence for the Decisions that Matter Most

Pathology's AI platform¹ for the experts answering medicine's biggest questions, from discovery through diagnosis.

Two scientists, one pointing at colorful medical images on dual computer monitors in a bright office.

Clinical LAB SOLUTIONS

At the point of review

An immersive, operationally intelligent review experience for pathology's experts.

CLINICAL

Smiling woman in lab coat looks at a computer screen displaying colorful scientific data.

Life Sciences SOLUTIONS

From tissue to treatment

Turn tissue into biomarker insights, move therapies through development and get them to the patients who need them.

LIFE SCIENCES

Trusted by 16 of the top 20 pharma companies and over 4,000 hospitals and clinics globally.

CONCENTRIQ

Pathology AI for
Precision Medicine

The Concentriq¹ portfolio powers precision medicine from discovery through diagnosis, with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review.

EXPLORE CONCENTRIQ

Woman focused on computer screen at her desk in a modern office setting.

Best in KLAS 2026

Concentriq is the highest-rated digital pathology platform in both the United States and Europe. Find out why we’re rated #1 by customers.

READ THE KLAS REPORT

Trusted at scale. Proven in practice.

12M

cases managed annually by Proscia's customers

4,000+

hospitals and clinics served worldwide

16 of 20

top pharmaceutical companies run on Concentriq

30,000+

studies powered by Concentriq, from discovery to trials

100%

of customers told KLAS they would buy Concentriq again

Middle-aged man with gray hair and beard wearing a white dress shirt standing with arms crossed by a large window in a bright office space.

FEATS OF STRENGTH VIDEO SERIES

The hardest part of going digital isn't the technology.

Behind every successful digital pathology deployment is a pathologist or lab leader who broke down barriers and moved their organization to Pathology AI. Feats of Strength tells their stories.

SEE THEIR STORIES

Smiling man with dark hair and beard wearing a dark suit, white shirt, and light blue tie against a blue gradient background.

"The only way to evolve, to make our discipline evolve, is go for more."

Dr. Luis Cano

Clinical AI & Digital Pathology Consultant

Portrait of a smiling young Asian man wearing round glasses, a black suit, white shirt, and a dark patterned tie, with a gradient light blue to gray background.

"Understanding the needs from all of those groups of people, their various perspectives, packaging them into a justification that made sense for everybody and showed value to the entire organization, those were some of the most critical steps that we undertook."

Dr. Cherub Kim

Director, Medical Affairs and Clinical Informatics Lead

Smiling woman with long light brown hair wearing a black blazer and hoop earrings on gradient blue background.

“Just go ahead and start. It’ll give you something to grow on.”

Dr. Amanda Hemmerich

Global Director of Digital Pathology Innovation
IQVIA Laboratories

Smiling middle-aged man with gray hair and glasses wearing a red sweater over a white shirt.

"I think the defining moment for me was when I saw that first scanner and saw what it could do. It was like, okay, someday, this is the way we're gonna work.”

Dr. Derrick Forchetti

Pathologist
South Bend Medical Foundation

Latest Resources

Blog

The Next Chapter in Proscia’s Mission

Proscia is being acquired by Agilent Technologies. Nathan Buchbinder, Coleman Stavish, and I started Proscia in our college dorm rooms with a big vision to rewire pathology for precision medicine and help change the way we fight diseases like cancer. Proscia has always been a long-term play – what would medicine look like in the next 50 years? 10 years after our founding, joining Agilent opens an exciting next chapter to accelerate our mission.

Press Release

Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence

SANTA CLARA, Calif. and PHILADELPHIA – October 13, 2026 – Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at $240 million in cash at closing and up to an additional $30 million based on achieving future performance milestones.

Webinar

Abstract swirling marble pattern in shades of teal, blue, white, beige, and burgundy.

Meet the Next Generation of Concentriq: Pathology’s AI Platform for Precision Medicine

Diagnostic labs and drug development programs are under more pressure than ever — and a pathology platform with AI bolted on can't keep up. See the first official demo of Concentriq Fifth Generation, built with an enterprise AI layer at its core. Hear directly from customers optimizing clinical diagnostic workflows and advancing drug development research.

Save my spot

View all

¹ The Concentriq portfolio includes distinct configurations. Concentriq AP-Dx is cleared for primary clinical diagnosis. Concentriq AP and Concentriq LS are for Research Use Only; not for use in diagnostic procedures. Proscia’s interoperable AI applications and native AI features are available for research use only on Concentriq AP. In some geographies, certain AI applications may be interoperable with Concentriq AP-Dx. Contact the AI application manufacturers for regulatory authorization status and indications for use. Proscia’s native AI features in Concentriq AP-Dx do not meet the definition of Artificial Intelligence as defined by Regulation (EU) 2024/1689.